Amgen Inc. (NASDAQ:AMGN) shares are trading lower on Wednesday, despite the company reporting second-quarter results that ...

Investing.com - 伯恩斯坦法兴集团周四将安进 (NASDAQ:AMGN)的目标价从350.00美元下调至335.00美元，同时维持对该股票的"优于大市"评级。根据 InvestingPro 数据，该股票目前的市盈率为23.5倍，分析师目标价范围从185美元到405美元不等。

Amgen on Tuesday posted quarterly financial results that beat Wall Street expectations as a 9% increase in product sales ...

Amgen on Tuesday posted quarterly financial results that beat Wall Street expectations as a 9% increase in product sales ...

Thousand Oaks-based Amgen saw shares dip about 5% on Aug. 6, the day after the company’s earnings announcement, though not because of the earnings themselves but rather about news of its weight-loss ...

More than one in five UK adults tried to access weight-loss medications in the past year alone, according to a survey by the ...

Explore Amgen's Q2 2025 earnings insights, showcasing 9% revenue growth, robust product performance, and innovation in obesity, rare disease, and ...

Amgen AMGN reported second-quarter 2025 adjusted earnings of $6.02 per share, which beat the Zacks Consensus Estimate of ...

Amgen Inc. (NASDAQ:AMGN) ranks among the best low volatility stocks to buy according to analysts. While keeping its Outperform rating, BMO Capital lowered its price target for Amgen Inc.

Amgen reported total revenue of $9.2 billion, topping the consensus of $8.9 billion, and non-GAAP earnings of $6.02 per share ...

该研究公司强调了安进的强劲销售表现，特别是其Evenity和Imdelltra产品，这些表现使Cantor Fitzgerald模型中的更高估计得到了证实。这一表现促成了安进稳健的股息状况，该公司已连续15年保持股息支付，目前收益率为3.3%。

Non-GAAP earnings per share for Q2 2025 beat estimates by 14.0%, rising to $6.02 (non-GAAP) and up 21% year over year (non-GAAP). Revenue increased 9% to $9.2 billion, exceeding analyst expectations ...